Neuroendocrine tumor in the breast

Ogawa, Hiroshi; Nishio, Akiko; Satake, Hiroko; Naganawa, Shinji; Imai, Tsuneo; Sawaki, Masataka; Yamamoto, Eiko; Miyata, Tomoko

doi:10.1007/s11604-007-0182-y

Cited by 50 publications

(52 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differential diagnoses include Merkel cell carcinoma, lymphoma, melanoma, and, above all, neuroendocrine tumors metastatic to the breast. The presence of an associated ductal carcinoma in situ component is a valid proof of the primary nature of the tumor [28]. However, when a NECB is diagnosed, a breast metastasis from other primary sites should be ruled out by appropriate imaging, such as a chest and abdomen computed tomography (CT) scan.…”

Section: Clinical Presentation and Diagnostic Work-upmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline-and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. The Oncologist 2016;21:28-32 Implications for Practice: Neuroendocrine carcinoma of the breast (NECB) is a distinct entity of breast cancer. Clinical features and morphology are not helpful to distinguish NECB from other subtypes of breast cancer; therefore, immunohistochemistry markers for neuroendocrine differentiation, mainly chromogranin and synaptophysin, should be routinely used to confirm the diagnosis, especially in cases of mucinous or solid papillary carcinoma in which the suspicion of NECB may be relevant. Adjuvant treatment should be offered according to the same recommendations given for the other types of invasive breast cancer. An accurate diagnosis of NECB is also important in the metastatic setting, in which a multimodality approach including specific therapies such as peptide receptor radionuclide therapy can be considered.

show abstract

Section: Clinical Presentation and Diagnostic Work-upmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

show abstract

“…NEBC are a rare entity of breast cancer [2] [3] [4]. In 1947, germanpathologisVolger [7] was the first to describe the existence of neuroendocrine cells in breast tissue and it was not until 1977, when Cubilla and Woodruff [8] reported the first eight cases of primary NEBC.…”

Section: Discussionmentioning

confidence: 99%

“…These tumors are rare. They account for less than 0, 1% of all breast cancers, and less than 1% of neuro-endocrine tumors [2] [3] [4]. Primary neuroendocrine breast carcinomas (NEBC) have been considered special features within conventional breast carcinomas until recently [5].…”

Section: Introductionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of the Breast: A Case Report and Review of the Literature

Bhiri¹,

Zaied²,

Mhabrech³

et al. 2017

OALib

View full text Add to dashboard Cite

show abstract

“…Population based statistics show that within the gastrointestinal tract, the small intestine is the most common site of carcinoids (45%) followed by rectum (20%), appendix (17%), colon (11%), stomach (7%). Far less common anatomical sites have been reported in literature, including breast, larynx, thymus and gall bladder [14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%